BRIEF-Novartis - Lutathera® Data Shows Significant PFS Improvement [Reuters]
Novartis AG (NVS)
Last novartis ag earnings: 4/28 01:00 am
Check Earnings Report
US:NYSE Investor Relations:
novartis.com/investors
Company Research
Source: Reuters
BRIEF-Novartis - Lutathera® Data Shows Significant PFS Improvement | Reuters 1 Min Read Oct 19 (Reuters) - Novartis AG: * ANNOUNCES PRESENTATION OF NEW LUTATHERA® NETTER-1 DATA AT ESMO DEMONSTRATING SIGNIFICANT IMPROVEMENT IN PFS REGARDLESS OF BASELINE LIVER TUMOR BURDEN * LUTATHERA TREATMENT WAS ASSOCIATED WITH A CLINICALLY SIGNIFICANT REDUCTION IN ESTIMATED RISK FOR DETERIORATION OF GLOBAL HEALTH STATUS (SELF-ASSESSMENT OF OVERALL HEALTH AND QUALITY OF LIFE) VERSUS COMPARATOR, * PROGRESSION FREE SURVIVAL (PFS) WAS ALSO IMPROVED IN PRESENCE OF ELEVATED ALKALINE PHOSPHATASE OR LARGE LESION AT BASELINE * LUTATHERA IS FIRST PEPTIDE RECEPTOR RADIONUCLIDE THERAPY (PRRT) TO RECEIVE REGULATORY REGISTRATION, WITH APPROVAL BY EUROPEAN COMMISSION IN SEPTEMBER 2017 AND BY US FOOD AND DRUG ADMINISTRATION (FDA) IN JANUARY 2018 Source text for Eikon: [ID:urn:newsml:newsroom:20181019:nNRA760ock:0] Further company coverage: (Berlin Speed Desk) All quotes delayed a minimum of 15 minutes. See here f
Show less
Read more
Impact Snapshot
Event Time:
NVS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVS alerts
High impacting Novartis AG news events
Weekly update
A roundup of the hottest topics
NVS
News
- Novartis (NVS) Increases Yet Falls Behind Market: What Investors Need to Know [Yahoo! Finance]Yahoo! Finance
- Food Allergy Treatment Drug Market to Register Immense Growth by 2032, Assesses DelveInsight | Key Companies - Vedanta Biosciences, Novartis, Alladapt Immunotherapeutics, Regeneron Pharmaceuticals, Genentech, Parexel [Yahoo! Finance]Yahoo! Finance
- Global Macular Degeneration Treatment Market to Soar to USD 23.29 Billion by 2029, Reveals Latest Industry Analysis [Yahoo! Finance]Yahoo! Finance
- Novartis (NVS) Declines More Than Market: Some Information for Investors [Yahoo! Finance]Yahoo! Finance
- 1 Magnificent Dividend Stock to Buy and Hold [Yahoo! Finance]Yahoo! Finance
NVS
Earnings
- 1/31/24 - Miss
NVS
Sec Filings
- 2/15/24 - Form S-8
- 2/2/24 - Form SC
- 1/31/24 - Form 6-K
- NVS's page on the SEC website